Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

Rhea-AI Summary

Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its first quarter 2025 financial results on May 8, 2025, after market close. Management will host a conference call at 4:30 p.m. (Eastern Time).

The company specializes in the Omnipod Insulin Management System, offering a tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.

©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403205687/en/

Investor Relations:

June Lazaroff

Senior Director, Investor Relations

(978) 600-7718

jlazaroff@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet (PODD) report Q1 2025 earnings?

Insulet will release Q1 2025 financial results on May 8, 2025, after market close, followed by a conference call at 4:30 p.m. ET.

How can investors access Insulet's (PODD) Q1 2025 earnings call?

Investors can access the call through the Investor Relations section at investors.insulet.com or by dialing (888) 770-7129 (US) or (929) 203-2109 (international) with passcode 5904836.

What is Insulet's (PODD) main product offering?

Insulet's main product is the Omnipod Insulin Management System, featuring a tubeless disposable Pod providing up to three days of continuous insulin delivery.

What are the key features of Insulet's (PODD) Omnipod 5 System?

The Omnipod 5 System offers automated insulin delivery, integrates with glucose monitors, requires no daily injections or fingersticks, and can be controlled via smartphone in the US.